Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) services involve companies providing specialized expertise and infrastructure for the development, manufacturing, and commercialization of cell and gene therapy products on behalf of biopharmaceutical companies. These services encompass a range of activities, including process development, analytical testing, regulatory support, and manufacturing at various scales, from preclinical to commercial production. CDMOs play a critical role in accelerating the translation of cell and gene therapies from research to clinical application by offering tailored solutions to meet the unique requirements of each therapy, ultimately helping to bring innovative treatments to patients more efficiently and effectively.
The global Cell and Gene Therapy CDMO Services market was valued at US$ 5598 million in 2023 and is anticipated to reach US$ 42510 million by 2030, witnessing a CAGR of 32.9% during the forecast period 2024-2030.
Due to complex technical mechanisms, high-threshold process development and large-scale production, strict regulatory requirements, and limited industrialization experience, CGT products are more dependent on CDMOs than traditional pharmaceuticals. Its outsourcing penetration rate exceeds 65%, far exceeding 35% of traditional biologics.
Considering that the production of viral vectors as the core involves very complex processes, is extremely difficult, and has a long preparation cycle, it is expected that the outsourcing rate of CGT will remain high in the future.
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy CDMO Services.
The Cell and Gene Therapy CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cell and Gene Therapy CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cell and Gene Therapy CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Catalent
Lonza
Thermo Fisher
WuXi AppTec
Charles River
OxfordBioMedica
BrammerBio
CELLfor CURE
OBiO Technology
GenScript
Esco
Nikon
FUJIFILM
Pharmaron
Porton
Medicilon
JOINN Laboratories
Sofpromed
eXmoor
OmniaBio
RoslinCT
BioCentriq
PolTREG
Miltenyi Bioindustry
Segment by Type
Autologous Cell Therapy Products
Allogeneic Cell Therapy Products
Segment by Application
SMBs
Large Companies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell and Gene Therapy CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell and Gene Therapy CDMO Services Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Autologous Cell Therapy Products
1.2.3 Allogeneic Cell Therapy Products
1.3 Market by Application
1.3.1 Global Cell and Gene Therapy CDMO Services Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy CDMO Services Market Perspective (2019-2030)
2.2 Global Cell and Gene Therapy CDMO Services Growth Trends by Region
2.2.1 Global Cell and Gene Therapy CDMO Services Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cell and Gene Therapy CDMO Services Historic Market Size by Region (2019-2024)
2.2.3 Cell and Gene Therapy CDMO Services Forecasted Market Size by Region (2025-2030)
2.3 Cell and Gene Therapy CDMO Services Market Dynamics
2.3.1 Cell and Gene Therapy CDMO Services Industry Trends
2.3.2 Cell and Gene Therapy CDMO Services Market Drivers
2.3.3 Cell and Gene Therapy CDMO Services Market Challenges
2.3.4 Cell and Gene Therapy CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell and Gene Therapy CDMO Services Players by Revenue
3.1.1 Global Top Cell and Gene Therapy CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Cell and Gene Therapy CDMO Services Revenue Market Share by Players (2019-2024)
3.2 Global Cell and Gene Therapy CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cell and Gene Therapy CDMO Services Revenue
3.4 Global Cell and Gene Therapy CDMO Services Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy CDMO Services Revenue in 2023
3.5 Global Key Players of Cell and Gene Therapy CDMO Services Head office and Area Served
3.6 Global Key Players of Cell and Gene Therapy CDMO Services, Product and Application
3.7 Global Key Players of Cell and Gene Therapy CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell and Gene Therapy CDMO Services Breakdown Data by Type
4.1 Global Cell and Gene Therapy CDMO Services Historic Market Size by Type (2019-2024)
4.2 Global Cell and Gene Therapy CDMO Services Forecasted Market Size by Type (2025-2030)
5 Cell and Gene Therapy CDMO Services Breakdown Data by Application
5.1 Global Cell and Gene Therapy CDMO Services Historic Market Size by Application (2019-2024)
5.2 Global Cell and Gene Therapy CDMO Services Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cell and Gene Therapy CDMO Services Market Size (2019-2030)
6.2 North America Cell and Gene Therapy CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cell and Gene Therapy CDMO Services Market Size by Country (2019-2024)
6.4 North America Cell and Gene Therapy CDMO Services Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell and Gene Therapy CDMO Services Market Size (2019-2030)
7.2 Europe Cell and Gene Therapy CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cell and Gene Therapy CDMO Services Market Size by Country (2019-2024)
7.4 Europe Cell and Gene Therapy CDMO Services Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size (2019-2030)
8.2 Asia-Pacific Cell and Gene Therapy CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size by Region (2019-2024)
8.4 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell and Gene Therapy CDMO Services Market Size (2019-2030)
9.2 Latin America Cell and Gene Therapy CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cell and Gene Therapy CDMO Services Market Size by Country (2019-2024)
9.4 Latin America Cell and Gene Therapy CDMO Services Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell and Gene Therapy CDMO Services Market Size (2019-2030)
10.2 Middle East & Africa Cell and Gene Therapy CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cell and Gene Therapy CDMO Services Market Size by Country (2019-2024)
10.4 Middle East & Africa Cell and Gene Therapy CDMO Services Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent Cell and Gene Therapy CDMO Services Introduction
11.1.4 Catalent Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.1.5 Catalent Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Cell and Gene Therapy CDMO Services Introduction
11.2.4 Lonza Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.2.5 Lonza Recent Development
11.3 Thermo Fisher
11.3.1 Thermo Fisher Company Details
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Cell and Gene Therapy CDMO Services Introduction
11.3.4 Thermo Fisher Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.3.5 Thermo Fisher Recent Development
11.4 WuXi AppTec
11.4.1 WuXi AppTec Company Details
11.4.2 WuXi AppTec Business Overview
11.4.3 WuXi AppTec Cell and Gene Therapy CDMO Services Introduction
11.4.4 WuXi AppTec Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.4.5 WuXi AppTec Recent Development
11.5 Charles River
11.5.1 Charles River Company Details
11.5.2 Charles River Business Overview
11.5.3 Charles River Cell and Gene Therapy CDMO Services Introduction
11.5.4 Charles River Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.5.5 Charles River Recent Development
11.6 OxfordBioMedica
11.6.1 OxfordBioMedica Company Details
11.6.2 OxfordBioMedica Business Overview
11.6.3 OxfordBioMedica Cell and Gene Therapy CDMO Services Introduction
11.6.4 OxfordBioMedica Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.6.5 OxfordBioMedica Recent Development
11.7 BrammerBio
11.7.1 BrammerBio Company Details
11.7.2 BrammerBio Business Overview
11.7.3 BrammerBio Cell and Gene Therapy CDMO Services Introduction
11.7.4 BrammerBio Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.7.5 BrammerBio Recent Development
11.8 CELLfor CURE
11.8.1 CELLfor CURE Company Details
11.8.2 CELLfor CURE Business Overview
11.8.3 CELLfor CURE Cell and Gene Therapy CDMO Services Introduction
11.8.4 CELLfor CURE Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.8.5 CELLfor CURE Recent Development
11.9 OBiO Technology
11.9.1 OBiO Technology Company Details
11.9.2 OBiO Technology Business Overview
11.9.3 OBiO Technology Cell and Gene Therapy CDMO Services Introduction
11.9.4 OBiO Technology Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.9.5 OBiO Technology Recent Development
11.10 GenScript
11.10.1 GenScript Company Details
11.10.2 GenScript Business Overview
11.10.3 GenScript Cell and Gene Therapy CDMO Services Introduction
11.10.4 GenScript Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.10.5 GenScript Recent Development
11.11 Esco
11.11.1 Esco Company Details
11.11.2 Esco Business Overview
11.11.3 Esco Cell and Gene Therapy CDMO Services Introduction
11.11.4 Esco Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.11.5 Esco Recent Development
11.12 Nikon
11.12.1 Nikon Company Details
11.12.2 Nikon Business Overview
11.12.3 Nikon Cell and Gene Therapy CDMO Services Introduction
11.12.4 Nikon Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.12.5 Nikon Recent Development
11.13 FUJIFILM
11.13.1 FUJIFILM Company Details
11.13.2 FUJIFILM Business Overview
11.13.3 FUJIFILM Cell and Gene Therapy CDMO Services Introduction
11.13.4 FUJIFILM Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.13.5 FUJIFILM Recent Development
11.14 Pharmaron
11.14.1 Pharmaron Company Details
11.14.2 Pharmaron Business Overview
11.14.3 Pharmaron Cell and Gene Therapy CDMO Services Introduction
11.14.4 Pharmaron Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.14.5 Pharmaron Recent Development
11.15 Porton
11.15.1 Porton Company Details
11.15.2 Porton Business Overview
11.15.3 Porton Cell and Gene Therapy CDMO Services Introduction
11.15.4 Porton Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.15.5 Porton Recent Development
11.16 Medicilon
11.16.1 Medicilon Company Details
11.16.2 Medicilon Business Overview
11.16.3 Medicilon Cell and Gene Therapy CDMO Services Introduction
11.16.4 Medicilon Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.16.5 Medicilon Recent Development
11.17 JOINN Laboratories
11.17.1 JOINN Laboratories Company Details
11.17.2 JOINN Laboratories Business Overview
11.17.3 JOINN Laboratories Cell and Gene Therapy CDMO Services Introduction
11.17.4 JOINN Laboratories Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.17.5 JOINN Laboratories Recent Development
11.18 Sofpromed
11.18.1 Sofpromed Company Details
11.18.2 Sofpromed Business Overview
11.18.3 Sofpromed Cell and Gene Therapy CDMO Services Introduction
11.18.4 Sofpromed Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.18.5 Sofpromed Recent Development
11.19 eXmoor
11.19.1 eXmoor Company Details
11.19.2 eXmoor Business Overview
11.19.3 eXmoor Cell and Gene Therapy CDMO Services Introduction
11.19.4 eXmoor Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.19.5 eXmoor Recent Development
11.20 OmniaBio
11.20.1 OmniaBio Company Details
11.20.2 OmniaBio Business Overview
11.20.3 OmniaBio Cell and Gene Therapy CDMO Services Introduction
11.20.4 OmniaBio Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.20.5 OmniaBio Recent Development
11.21 RoslinCT
11.21.1 RoslinCT Company Details
11.21.2 RoslinCT Business Overview
11.21.3 RoslinCT Cell and Gene Therapy CDMO Services Introduction
11.21.4 RoslinCT Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.21.5 RoslinCT Recent Development
11.22 BioCentriq
11.22.1 BioCentriq Company Details
11.22.2 BioCentriq Business Overview
11.22.3 BioCentriq Cell and Gene Therapy CDMO Services Introduction
11.22.4 BioCentriq Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.22.5 BioCentriq Recent Development
11.23 PolTREG
11.23.1 PolTREG Company Details
11.23.2 PolTREG Business Overview
11.23.3 PolTREG Cell and Gene Therapy CDMO Services Introduction
11.23.4 PolTREG Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.23.5 PolTREG Recent Development
11.24 Miltenyi Bioindustry
11.24.1 Miltenyi Bioindustry Company Details
11.24.2 Miltenyi Bioindustry Business Overview
11.24.3 Miltenyi Bioindustry Cell and Gene Therapy CDMO Services Introduction
11.24.4 Miltenyi Bioindustry Revenue in Cell and Gene Therapy CDMO Services Business (2019-2024)
11.24.5 Miltenyi Bioindustry Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Catalent
Lonza
Thermo Fisher
WuXi AppTec
Charles River
OxfordBioMedica
BrammerBio
CELLfor CURE
OBiO Technology
GenScript
Esco
Nikon
FUJIFILM
Pharmaron
Porton
Medicilon
JOINN Laboratories
Sofpromed
eXmoor
OmniaBio
RoslinCT
BioCentriq
PolTREG
Miltenyi Bioindustry
*If Applicable.